Blonanserin versus risperidone for schizophrenia
Referencias
Additional references
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
Alvarez‐Jimenez M, Gonzalez‐Blanch C, Vazquez‐Barquero JL, Perez‐Iglesias R, Martinez‐Garcia O, Perez‐Pardal T, et al. Attenuation of antipsychotic‐induced weight gain with early behavioral intervention in drug‐naive first‐episode psychosis patients: a randomized controlled trial. Journal of Clinical Psychiatry 2006;67(8):1253‐60. [PUBMED: 16965204]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. American Psychiatric Association, 2013.
Andrew A, Knapp M, McCrone P, Parsonage M, Trachtenberg M. Effective Interventions in Schizophrenia the Economic Case: A Report Prepared for the Schizophrenia Commission. Vol. 1, London: London School of Economics and Political Science, Personal Social Services Research Unit, 2012.
Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. NIHR Health Technology Assessment Programme 2003;7(13):1‐193.
Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]
Crossley NA, Constante M, McGuire P. Efficacy of atypical versus typical antipsychotics in the treatment of early psychosis: meta‐analysis. British Journal of Psychiatry 2010;196:434‐9.
Deeks J. Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Deeks ED, Keating GM. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 2010;24(1):65‐84. [PUBMED: 20030420]
Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10.
Ghosh R, Bhatia MS, Bhattacharya SK. Blonanserin in management of schizophrenia. Delhi Psychiatry Journal 2012;15(1):406‐11.
Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Flavio Guzman. Risperidone Indications: FDA‐Approved and Off‐Label Uses. psychopharmacologyinstitute.com/antipsychotics/risperidone/risperidone‐indications‐fda‐approved‐and‐off‐label‐uses/ (accessed: August 28, 2016).
Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20 year multi‐follow‐up study. Psychological Medicine 2014;44:3007‐16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27–30.
World Health Organisation. International Statistical Classifiction of Diseases and Related Health Problems. Vol. 2, World Health Organisation, 2010.
Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005237.pub2; PUBMED: 16625629]
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Keks NA, Culhane C. Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opinion on Investigational Drugs 1999;8(4):443‐52.
Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophrenia Research 2008;106(2‐3):89‐107. [PUBMED: 18799287]
Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]
Li H, Yao C, Shi J, Yang F, Qi S, Wang L, et al. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double‐blind, parallel‐group multicenter randomized trial. Journal of Psychiatric Research 2015;31(69):102‐9.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30:67–76.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005;10:79‐104.
Miyamoto S, Miyake N, Jarkskog LF, Fleishhacker WW, Lieberman JA. Pharmacological treatment of schizoprenia: a critical review of the pharmacology and clinical effects on current and future theraputic agents. Molecular Psychiatry 2012;17(12):1206‐27.
Mizarhi R, Bagby RM, Zipursky RB, Kapur S. Why don't patients take their medicine?. Advances in Psychiatric Treatment 2005;13:336‐46.
Murphy B, Chung YC, Park TW, McGorry P. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophrenia Research 2006;88:5‐25.
Murray CL, Lopez AD. The Global Burden of Disease. Cambridge: Harvard University Press, 1996..
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Sanz‐Fuentenebro J, Taboada D, Palomo T, Aragues M, Overjero S, Del‐Alamo C, et al. Randomised control trial of clozapone vs. risperidone in treatment‐naive first‐episode schizophrenia: results after one year. Schizophrenia Research 2013;149:156‐61.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Sham PC, Maclean CJ, Kendler KS. A typological model of schizophrenia based on age at onset, sex and familial morbidity. Acta Psychiatrica Scandinavica 1994;89(2):135‐41. [PUBMED: 8178665]
Sterne JAC, Egger M, Moher D, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Sumitomo Pharmaceutical (Suzhou) Co, Ltd. Efficiency study to investigate blonanserin in treatment of schizophrenia when compared with risperidone. https://clinicaltrials.gov/ct2/show/NCT01516424 (first received 18 January 2012).
Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophrenia Research 2008;100(1‐3):4‐19. [PUBMED: 18291627]
Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research 2008;102(1‐3):1‐18. [PUBMED: 18514488]
Tenjin T, Miyamoto S, Ninomiva Y, Kitajima R, Ogino S, Miyake N, et al. Profile of blonanserin for the treatment of schizophrenia. Journal of Neuropsychiatric Disease and Treatment 2013;9:587‐94.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75.
Une T, Kurumiya S. Pharmacological profile of blonanserin. Japanese Jouranal of Clinical Psychopharmacology 2007;10(7):1263‐72.
World Health Organisation. Mental Health, Schizophrenia. www.who.int/mental_health/management/schizophrenia/en/(accessed July 2016).
Wong MM, Chen EYH, Lui SS, Tso S. Medication adherence and subjective weight perception in patients with first‐episode psychotic disorder. Clinical and Schizophrenia Related Psychosis 2011;5:135‐41.
Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Figuras y tablas -
Figure 1
Blonanserin ‐ structure
Figuras y tablas -
Figure 2
Risperidone ‐ structure
